Scholarlink

<p>The BRAF<sup><i>V600E</i></sup> mutation is a key oncogenic driver in multiple cancers. While FDA-approved BRAF inhibitors exist, their efficacy is often limited by drug resistance and adverse effects, necessitating the discovery of novel therapeutic agents. This study aimed to computationally repurpose clinically approved drugs as potential BRAF inhibitors. A ligand-based pharmacophore model was generated using five known BRAF inhibitors and validated to identify a robust three-feature hypothesis (one hydrogen bond acceptor and two aromatic rings). This model was used to screen the E-Drug3D database of FDA-approved drugs, yielding 666 initial hits. Subsequent structure-based virtual screening, molecular docking, and molecular dynamics simulations against both wild-type BRAF and BRAF<sup><i>V600E</i></sup> identified several promising candidates. Ticagrelor emerged as a top hit, demonstrating a stable binding mode and favorable molecular dynamics profile comparable to the reference inhibitor regorafenib. Experimental validation in colorectal cancer cell lines with varying BRAF status revealed that ticagrelor, along with other identified drugs like pioglitazone and nilotinib, exhibited significant anti-proliferative and pro-apoptotic effects. These findings suggest that ticagrelor is a promising repurposing candidate for BRAF inhibition and provide a foundation for overcoming current challenges in targeted cancer therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

In silico repurposing of clinically approved drugs as potential BRAF inhibitors: a pharmacophore-based virtual screening and experimental investigation

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月23日

查看全文
  • Hooriehsadat Amini,
  • Negin Ebrahimi,
  • Sayedali Mousavirahimi,
  • Mozhdeh Zamani,
  • Kowsar Bagherzadeh,
  • Hamed Montazeri,
  • Homa Azizian

摘要

The BRAFV600E mutation is a key oncogenic driver in multiple cancers. While FDA-approved BRAF inhibitors exist, their efficacy is often limited by drug resistance and adverse effects, necessitating the discovery of novel therapeutic agents. This study aimed to computationally repurpose clinically approved drugs as potential BRAF inhibitors. A ligand-based pharmacophore model was generated using five known BRAF inhibitors and validated to identify a robust three-feature hypothesis (one hydrogen bond acceptor and two aromatic rings). This model was used to screen the E-Drug3D database of FDA-approved drugs, yielding 666 initial hits. Subsequent structure-based virtual screening, molecular docking, and molecular dynamics simulations against both wild-type BRAF and BRAFV600E identified several promising candidates. Ticagrelor emerged as a top hit, demonstrating a stable binding mode and favorable molecular dynamics profile comparable to the reference inhibitor regorafenib. Experimental validation in colorectal cancer cell lines with varying BRAF status revealed that ticagrelor, along with other identified drugs like pioglitazone and nilotinib, exhibited significant anti-proliferative and pro-apoptotic effects. These findings suggest that ticagrelor is a promising repurposing candidate for BRAF inhibition and provide a foundation for overcoming current challenges in targeted cancer therapy.